Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5881 to 5895 of 7682 results

  1. Self-management materials: What is the effectiveness and cost effectiveness of rehabilitation programmes combined with self-management materials, compared with rehabilitation programmes alone, in people with complex rehabilitation needs after a traumatic injury?

    Recommendation ID NG211/04 Question Self-management materials: What is the effectiveness and cost effectiveness of rehabilitation programmes

    Research recommendation
    Published
    1 February 2022

  2. Length of bed rest after spinal cord injury: What is the effectiveness and cost effectiveness of short-term bed rest compared with long-term bed rest on functional outcomes in people with complex rehabilitation needs after traumatic injury that involves the spinal column or spinal cord injury?

    Recommendation ID NG211/05 Question Length of bed rest after spinal cord injury: What is the effectiveness and cost effectiveness of short-term

    Research recommendation
    Published
    1 February 2022

  3. What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?

    Recommendation ID NG191/3 Question What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs)

    Research recommendation
    Published
    10 August 2021

  4. What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

    Recommendation ID NG191/2 Question What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis

    Research recommendation
    Published
    10 August 2021

  5. What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2 variants?

    Recommendation ID NG191/15 Question What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2

    Research recommendation
    Published
    9 March 2022

  6. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    Recommendation ID NG191/1 Question What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological

    Research recommendation
    Published
    10 August 2021

  7. Advocacy and support for decision-making:- What is the effectiveness, cost effectiveness and acceptability of advocacy as a means of supporting people to make decisions?

    Recommendation ID NG108/3 Question Advocacy and support for decision-making:- What is the effectiveness, cost effectiveness and acceptability

    Research recommendation
    Published
    18 December 2018

  8. Dementia education and training programmes for family members and carers:- What is the effectiveness, cost effectiveness and acceptability of training programmes (forexample, in the use of life story work) for families of people growing older with learning disabilities who have dementia or are at risk of developing it?

    Recommendation ID NG96/4 Question Dementia education and training programmes for family members and carers:- What is the effectiveness

    Research recommendation
    Published
    29 November 2018

  9. What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

    Recommendation ID NG191/8 Question What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab

    Research recommendation
    Published
    21 October 2021

  10. What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19?

    Recommendation ID NG191/7 Question What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab

    Research recommendation
    Published
    12 November 2021

  11. Targeted support: What is the effectiveness (including long-term effectiveness) and cost effectiveness of targeted group or individual interventions for children and young people who have been identified as needing additional mental health support, and does it vary by ethnicity, socioeconomic status or other cultural and personal factors?

    Recommendation ID NG223/03 Question Targeted support: What is the effectiveness (including long-term effectiveness) and cost effectiveness

    Research recommendation
    Published
    4 August 2022

  12. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    Recommendation ID CG181/1 Question What is the effectiveness of age alone and other routinely available risk factors compared with the

    Research recommendation
    Published
    9 June 2015

  13. Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of seasonal versus continuous prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    Recommendation ID NG115/9 Question Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of seasonal

    Research recommendation
    Published
    13 February 2019

  14. Rate-control drug treatment for people aged 75 and over with atrial fibrillation: What is the comparative effectiveness of the 3 main drug classes used for rate control (beta‑blockers, calcium‑channel blockers and digoxin) in people aged 75 and over with atrial fibrillation in controlling symptoms, improving quality of life and reducing morbidity and mortality?

    Recommendation ID NG196/6 Question Rate-control drug treatment for people aged 75 and over with atrial fibrillation: What is the comparative

    Research recommendation
    Published
    10 August 2021

  15. Psychologically informed environments: What is the effectiveness and acceptability of clinical psychology-led psychologically informed environments and psychological approaches for people experiencing homelessness?

    Recommendation ID NG214/01 Question Psychologically informed environments: What is the effectiveness and acceptability of clinical psychology-led

    Research recommendation
    Published
    8 April 2022